Regenxbio Inc
RGNX
查看详细走势图
14.160USD
-0.300-2.07%
收盘 12/26, 16:00（美东）报价延迟15分钟
716.77M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-2.07%
5天
-2.95%
1月
+6.79%
6月
+68.77%
今年开始到现在
+83.18%
1年
+91.09%
查看详细走势图
TradingKey Regenxbio Inc股票评分
单位: USD 更新时间: 2025-12-26操作建议
Regenxbio Inc当前公司基本面数据相对稳定，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名80/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价31.46。中期看，股价处于上升通道。近一个月，市场表现较强，技术面和基本面综合得分较高，较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Regenxbio Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
13
位分析师
买入
评级
31.462
目标均价
+137.62%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Regenxbio Inc亮点
亮点风险
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
业绩增长期
公司处于发展阶段，最新年度总收入83.33M美元
估值低估
公司最新PE估值-4.09，处于3年历史低位
机构减仓
最新机构持股44.05M股，环比减少11.47%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值18.92K
Regenxbio Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Regenxbio Inc简介
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
公司代码RGNX
公司Regenxbio Inc
CEOSimpson (Curran M)
网址https://regenxbio.com/
常见问题
Regenxbio Inc(RGNX)的当前股价是多少？
Regenxbio Inc(RGNX)的当前股价是 14.160。
Regenxbio Inc的股票代码是什么？
Regenxbio Inc的股票代码是RGNX。
Regenxbio Inc股票的52周最高点是多少？
Regenxbio Inc股票的52周最高点是15.410。
Regenxbio Inc股票的52周最低点是多少？
Regenxbio Inc股票的52周最低点是5.035。
Regenxbio Inc的市值是多少？
Regenxbio Inc的市值是716.77M。
Regenxbio Inc的净利润是多少？
Regenxbio Inc的净利润为-227.10M。
现在Regenxbio Inc(RGNX)的股票是买入、持有还是卖出？
根据分析师评级，Regenxbio Inc(RGNX)的总体评级为买入，目标价格为31.462。
Regenxbio Inc(RGNX)股票的每股收益（EPS TTM）是多少
Regenxbio Inc(RGNX)股票的每股收益（EPS TTM）是-3.461。
相关品种
